Clinical Effect And Mechanism Of Lyophilized Recombinant Human Brain Natriuretic In The Treatment Of Patients With Cardiac Insufficiency

BackgroundHeart failure is a kind of clinical syndrome caused by various reasons,which lead to the change of cardiac structure and function.Heart failure,especially acute heart failure or acute exacerbation of chronic heart failure with a very high mortality,and prone to recurrent.So it is very important to reduce the mortality rate and improve the quality of life in patients with heart failure.At present,there is still a lack of effective therapeutic drugs in clinic.In recent years,lyophilized recombinant human brain natriuretic(new living elements)provide a new therapeutic method for the clinical treatment of heart failure,especially the acute attack of chronic heart failure or acute heart failure.The purpose of this study was to analyze the clinical efficacy and mechanism of action of lyophilized recombinant human brain natriuretic in the treatment of heart failure patients,so as to provide some guidance for clinical treatment.ObjectiveLyophilized recombinant human brain natriuretic therapy in heart failure patients clinical efficacy and mechanism of action.MethodsThe 82 patients hospitalized with heart failure were randomly divided into observation group 41 cases and control group 41 cases.Control group with conventional treatment,observation group therapy combined with new active element in the control group basis.The treatment lasted 7d.Comparative efficacy of two groups of patients before and after treatment of heart rate,systolic blood pressure,stroke volume(SV),leftventricular ejection fraction(LVEF),central venous pressure(CVP),nitric oxide(NO),endothelin-1(ET-1)during treatment and poor before the N-terminal brain natriuretic peptide(NT-pro BNP)reaction conditions.Results1.the total effective rate of the observation group(92.68%)was higher than that of the control group(73.17%),and there was a significant difference(P<0.05);2.two groups after treatment,heart rate decreased,and there was significant difference(P<0.05),systolic blood pressure before and after treatment no significant difference(P>0.05);after treatment was observed in heart rate was significantly lower than the control group(P<0.05);3.two groups heart function indexes of LVEF,SV,CVP before treatment,no significant difference(P>0.05);two groups of indices of cardiac function after treatment LVEF,SV increased significantly,and after treatment with CVP decreased significantly,and there were statistically differences(P<0.05);observation group indices of cardiac function after treatment,LVEF and SV is higher than that of the control group,and after treatment with CVP below in the control group(P<0.05);4.plasma NT-proBNP levels in the treatment had no statistically significant difference(P>0.05);obviously decreased after plasma NT-proBNP levels in the treatment,and there were statistical difference(P<0.05);observation group,the levels of plasma NT-proBNP lower than that of the control group(P<0.05);5.two groups of serum NO and ET-1 levels before treatment there is no statistical difference(P>0.05);serum NO level in two groups after treatment significantly increased,and ET-1 levels after treatment decreased significantly,and there was a significant difference(P<0.05);treatment group,the serum NO level higher than control group,and ET-1 levels after treatment below the control group,and there were significant differences in the(P<0.05);6.no serious adverse drug reactions occurred in the two groups during the periodof drug treatment.Conclusion1.Lyophilized recombinant human brain natriuretic treatment treatment of heart failure safe and effective;2.Mechanism may improve vascular endothelial function.